News

Currently, the company is developing hGH-CTP in Phase II trial as a treatment for growth harmone deficiency in children. Earlier, Prolor has released interim results from a Phase

The nutrition research program will be conducted in collaboration with a strategic partner, the Institute of Nutraceuticals and Functional Foods (INAF). INAF dedicates all of its research efforts

The launching of the product follows the US Food and Drug Administration’s (FDA) approval of abbreviated new drug application (ANDA) for Levofloxacin tablets. According to the company, Levofloxacin

TH-302 is a novel small molecule tumor selective hypoxia-activated prodrug (HAP) that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors. Earlier, the

BT-061 is a humanized monoclonal antibody that works by activating the body’s T-regulatory cells, a subset of T-cells, strengthening a natural function of the body that prevents excessive

Earlier, following its inspection in March, the FDA issued a list of observed deviations from current Good Manufacturing Practice (GMP). In return, the company responded to the FDA’s

The lawsuit was filed in connection with Sun Pharma‘s submission of abbreviated new drug application (ANDA) seeking marketing rights for the generic versions of Depomed‘s 500mg and 1000mg

Exco’s eDiary will allow patients to participate in the trial irrespective of their location, age or proximity to the site. The study, which will focus on new research

The EU marketing authorization of BYDUREON is based on review of the submission package, including data from studies in the DURATION clinical program in which exenatide resulted in